A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
Stopped A business decision made by Incyte after analysis of data from a sister study.
Conditions
Interventions
- DRUG: Epacadostat
- DRUG: Nivolumab
- DRUG: Ipilimumab
- DRUG: Lirilumab
Sponsor
Incyte Corporation